Lewy Body Dementias: Controversies and Drug Development.
Clinical trial as topic [MeSH term]
Dementia with Lewy bodies
Drug therapy [MeSH term]
Lewy body dementia [MeSH term]
Parkinson disease dementia
Treatment
Journal
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
ISSN: 1878-7479
Titre abrégé: Neurotherapeutics
Pays: United States
ID NLM: 101290381
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
accepted:
06
11
2021
medline:
1
1
2022
pubmed:
1
1
2022
entrez:
4
1
2024
Statut:
ppublish
Résumé
Lewy body dementia (LBD) is one of the most common neurodegenerative dementias. Clinical trials for symptomatic and disease-modifying therapies in LBD remain a national research priority, but there are many challenges in both past and active drug developments in LBD. This review highlights the controversies in picking the appropriate populations, interventions, target selections, and outcome measures, which are all critical components of clinical trial implementation in LBD. The heterogeneity of LBD neuropathology and clinical presentations, limited understanding of core features such as cognitive fluctuations, and lack of validated LBD-specific outcome measures and biomarkers represent some of the major challenges in LBD trials.
Identifiants
pubmed: 38176809
pii: S1878-7479(23)00153-8
doi: 10.1007/s13311-021-01161-z
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
55-67Informations de copyright
Copyright © 2022 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier Inc. All rights reserved.